Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>= 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t).

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center Erasmus MC - Daniel den Hoed Postbus 5201 3008 AE RotterdamTel: 010 7041560 Fax: 010 7041028 e-mail: hdc@erasmusmc.nl0 个研究点目标入组 126 人开始时间: 待定最近更新: 2024年2月28日

研究概览

简要总结

/A

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Age 60 years or more;
•2. Subjects with a cytopathologically confirmed diagnosis of:

排除标准

•1. Extramedullary disease;
•2. Planned allogeneic hematopoietic cell transplantation;

研究者

发起方

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center Erasmus MC - Daniel den Hoed Postbus 5201 3008 AE RotterdamTel: 010 7041560 Fax: 010 7041028 e-mail: hdc@erasmusmc.nl

相似试验

进行中（未招募）

不适用

Study for the treatment of patients who have been succesfully treated for leukemia before, to keep the patient leukemia freeAcute myeloid leukemia

EUCTR2008-001290-15-NLHOVON Foundation126

进行中（未招募）

不适用

Study for the treatment of patients who have been succesfully treated for leukemia before, to keep the patient leukemia free.Acute myeloid leukemia

EUCTR2008-001290-15-BEHOVON Foundation126

已完成

3 期

Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (>= 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t)10024324Acute myeloid leukemialeukemia

NL-OMON37945HOVO86

已完成

2 期

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)Stem Cell TransplantationLeukemia

NCT00813124M.D. Anderson Cancer Center24

已完成

3 期

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia

NCT01074047Celgene488